• Multiple Myeloma News
    • Jun 09, 2018

    SparkCures Founder Brian McMahon Named One of “40 Under 40 in Cancer”

Brian McMahon, CEO & Founder of SparkCures, was recently named as one of the nation’s top “40 under 40 in Cancer.” This award, which was presented during a cocktail reception on June 2, 2018 in Chicago, was created by The Lynx Group™ and McGivney Global Advisors, as a means of celebrating the contributions that individuals under the age of 40 are making to improve the lives of those affected by cancer.

“I think Brian McMahon is saving lives, and he is absolutely dedicated to eradicating this disease,” says Sheila Miller, the multiple myeloma patient who nominated Brian for the award. “He and his company, SparkCures, find clinical trials for multiple myeloma patients, and don’t charge them a dime for doing so. He does all of this with the warmest, most caring personality imaginable. He truly is a remarkable source of encouragement and strength for so many people who are faced with this disease.”

Brian, a four time cancer caregiver, is deeply passionate about helping cancer patients understand and discover their clinical trial options. SparkCures currently focuses on Multiple Myeloma – a cancer of the bone marrow that Brian lost his mother to in 2007.

“It means so much to me to have been nominated for this award by patients that I have worked with – and I’m so honored to have been selected. The search for clinical trials takes on a very personal note for me. My mother’s initial prognosis was incredibly poor and within three weeks, we had her enrolled in a clinical trial. Participating in that trial gave my family two additional years with my mother that the doctors never thought would be possible. Clinical trials may not be the right choice for every patient, but our goal at SparkCures is to help patients understand all of their options. I want them to know that they are never alone. That’s why I started SparkCures, and I’m so grateful to be able to help them through difficult times.” says McMahon.

Nominations for the 40 Under 40 in Cancer award came from across the country and represented the following categories: clinical and patient care; biopharma, diagnostics and devices; research, science and technology; government, regulatory and payer; and patient advocacy and policy. Members of the 2018 inaugural class were selected by a panel of judges.

“Early-career leaders in oncology — clinicians, researchers, business people, advocates — are making an enormous impact on patients and the cancer community, but many of these individuals have not had the opportunity to be widely recognized,” says McGivney Global Advisors Partner and cancer survivor Jennifer Hinkel. “40 under 40 in Cancer is an effort to highlight the contributions of these rising stars.”

“These individuals are tomorrow’s driving force in innovation,” adds Brian Tyburski, President and CEO, The Lynx Group™. “Their achievements are crucial, well deserved, and should be applauded by all. We’re proud to partner with McGivney Global Advisors in honoring these 40 individuals for their outstanding achievements and contributions within their respective roles in the cancer continuum.” 

More information about the award, nomination process and the “40 Under 40 in Cancer” awards ceremony and recipients can be found at 40under40incancer.com.

Originally taken from McGivney Global Advisors and The Lynx Group.

About Author

MYELOMA CROWD RESEARCH INITIATIVE
$51,091 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: